Please ensure Javascript is enabled for purposes of website accessibility

Why BioNTech Blew Past the Market on Wednesday

By Eric Volkman - Jun 9, 2021 at 6:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The U.S. government plans to buy hundreds of millions more doses of the company's COVID-19 vaccine to donate to poorer countries.

What happened

Coronavirus vaccine developer BioNTech (BNTX 0.21%) had a happy hump day, with its shares rising 9.5% -- in sharp contrast to the S&P 500 index, which declined by a fraction. The company's high-demand product is getting another big lift from the public sector.

So what

The Biden administration reportedly plans to buy 500 million doses of BNT162b2 for distribution abroad. That's according to a Washington Post report published Wednesday morning, citing "three people familiar with the plans."

Pregnant woman receiving a vaccine jab.

Image source: Getty Images.

The doses will be donated to low- and middle-income countries, as part of the administration's previously stated goal of helping such nations fight the pandemic. COVAX, the global coronavirus vaccine initiative, will distribute the jabs.

BNT162b2 is the vaccine developed by BioNTech in collaboration with global pharmaceutical heavyweight Pfizer (PFE 1.17%). It has been authorized for use in both the European Union and the U.S. It is one of only three coronavirus vaccines given the green light by the FDA.

According to the article's sources, Biden will announce the government's new initiative at the Group of Seven meeting later this week in the U.K. Pfizer CEO Albert Bourla will reportedly be at his side when he does so.

Now what

The U.S. government's obvious confidence in the Pfizer/BioNTech vaccine burnishes its reputation, and it will continue to be a key instrument in keeping the still-deadly coronavirus at bay. By extension, this will enhance BioNTech's stature and keep attention focused on the solid work of the German biotech.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
$147.92 (0.21%) $0.31
Pfizer Inc. Stock Quote
Pfizer Inc.
$49.15 (1.17%) $0.57

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.